Your browser doesn't support javascript.
loading
Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification.
Sethi, Sanjeev; Beck, Laurence H; Glassock, Richard J; Haas, Mark; De Vriese, An S; Caza, Tiffany N; Hoxha, Elion; Lambeau, Gérard; Tomas, Nicola M; Madden, Benjamin; Debiec, Hanna; D'Agati, Vivette D; Alexander, Mariam P; Amer, Hatem; Appel, Gerald B; Barbour, Sean J; Caravaca-Fontan, Fernando; Cattran, Daniel C; Casal Moura, Marta; D'Avila, Domingos O; Eick, Renato G; Garovic, Vesna D; Greene, Eddie L; Herrera Hernandez, Loren P; Jennette, J Charles; Lieske, John C; Markowitz, Glen S; Nath, Karl A; Nasr, Samih H; Nast, Cynthia C; Pani, Antonello; Praga, Manuel; Remuzzi, Giuseppe; Rennke, Helmut G; Ruggenenti, Piero; Roccatello, Dario; Soler, Maria Jose; Specks, Ulrich; Stahl, Rolf A K; Singh, Raman Deep; Theis, Jason D; Velosa, Jorge A; Wetzels, Jack F M; Winearls, Christopher G; Yandian, Federico; Zand, Ladan; Ronco, Pierre; Fervenza, Fernando C.
Afiliación
  • Sethi S; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: sethi.sanjeev@mayo.edu.
  • Beck LH; Section of Nephrology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Glassock RJ; Department of Medicine, Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California, USA.
  • Haas M; Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • De Vriese AS; Division of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge, Brugge, Belgium; Department of Internal Medicine, Ghent University, Ghent, Belgium.
  • Caza TN; Arkana Laboratories, Little Rock, Arkansas, USA.
  • Hoxha E; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Lambeau G; Université Côte d'Azur, Centre National de la Recherche Scientifique, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne Sophia Antipolis, France.
  • Tomas NM; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Madden B; Mayo Clinic Proteomics Core, Mayo Clinic, Rochester, Minnesota, USA.
  • Debiec H; Sorbonne Université, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S 1155, Paris, France.
  • D'Agati VD; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
  • Alexander MP; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Amer H; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Appel GB; Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, New York, USA.
  • Barbour SJ; Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Caravaca-Fontan F; Department of Medicine, Complutense University, Instituto de Investigación Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Cattran DC; Toronto General Research Institute, Division of Nephrology, University of Toronto, Toronto, Ontario, Canada.
  • Casal Moura M; Division of Pulmonary and Critical Care, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • D'Avila DO; Serviço de Nefrologia, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
  • Eick RG; Serviço de Nefrologia, Hospital Moinhos de Vento, Porto Alegre, Rio Grande do Sul, Brazil.
  • Garovic VD; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Greene EL; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Herrera Hernandez LP; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Jennette JC; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Lieske JC; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Markowitz GS; Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
  • Nath KA; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Nasr SH; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Nast CC; Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Pani A; Nephrology, Dialysis and Transplantation, Arnas Brotzu, Cagliari, Italy; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
  • Praga M; Department of Medicine, Complutense University, Instituto de Investigación Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Remuzzi G; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Rennke HG; Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Ruggenenti P; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy; Unit of Nephrology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
  • Roccatello D; Nephrology and Dialysis Unit, San Giovanni Bosco Hub Hospital, ASL Città di Torino, Turin, Italy; Center of Immuno-Rheumatology and Rare Diseases (CMID), Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
  • Soler MJ; Department of Nephrology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, Barcelona, Spain; Centro de Referencia en Enfermedad, Glomerular Compleja del Sistema Nacional de Salud de España (CSUR), Barcelona, Spain.
  • Specks U; Division of Pulmonary and Critical Care, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Stahl RAK; III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Singh RD; Renal Pathophysiology Research, Mayo Clinic, Rochester, Minnesota, USA.
  • Theis JD; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Velosa JA; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Wetzels JFM; Department of Nephrology, Radboud Institute of Health Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Winearls CG; Renal Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Yandian F; Department of Nephrology, Hospital de Clinicas Universidad de la Republica, Montevideo, Uruguay.
  • Zand L; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
  • Ronco P; Sorbonne Université, Paris, France; Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S 1155, Paris, France; Division of Nephrology, Centre Hospitalier du Mans, Le Mans, France.
  • Fervenza FC; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: fervenza.fernando@mayo.edu.
Mayo Clin Proc ; 98(11): 1671-1684, 2023 11.
Article en En | MEDLINE | ID: mdl-37804268
ABSTRACT
Membranous nephropathy (MN) is a pattern of injury caused by autoantibodies binding to specific target antigens, with accumulation of immune complexes along the subepithelial region of glomerular basement membranes. The past 20 years have brought revolutionary advances in the understanding of MN, particularly via the discovery of novel target antigens and their respective autoantibodies. These discoveries have challenged the traditional classification of MN into primary and secondary forms. At least 14 target antigens have been identified, accounting for 80%-90% of cases of MN. Many of the forms of MN associated with these novel MN target antigens have distinctive clinical and pathologic phenotypes. The Mayo Clinic consensus report on MN proposes a 2-step classification of MN. The first step, when possible, is identification of the target antigen, based on a multistep algorithm and using a combination of serology, staining of the kidney biopsy tissue by immunofluorescence or immunohistochemistry, and/or mass spectrometry methodology. The second step is the search for a potential underlying disease or associated condition, which is particularly relevant when knowledge of the target antigen is available to direct it. The meeting acknowledges that the resources and equipment required to perform the proposed testing may not be generally available. However, the meeting consensus was that the time has come to adopt an antigen-based classification of MN because this approach will allow for accurate and specific MN diagnosis, with significant implications for patient management and targeted treatment.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glomerulonefritis Membranosa Límite: Humans Idioma: En Revista: Mayo Clin Proc Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glomerulonefritis Membranosa Límite: Humans Idioma: En Revista: Mayo Clin Proc Año: 2023 Tipo del documento: Article